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Introduction
Recombinant IL-1 receptor antagonist (anakinra) is an
effective treatment in a subgroup of systemic onset JIA
(SoJIA). So far no information is available on the long
term follow-up of SoJIA patients treated with anakinra.
Objectives
To analyse the long term follow-up of SoJIA patients
treated with Anakinra in a single tertiary referral center.
Methods
Since 2005, 34 SoJIA patients (19 M, 15 F) were treated
with anakinra at the staring dose of 1-2 mg/kg/die. Com-
plete response was defined as the absence of systemic and
articular manifestations and normal acute phase reactants
at follow-up, with anakinra as a monotherapy. Other
patients were considered as partial responders (still in ana-
kinra with evidence of disease activity) or non-responders
(withdrawn of Anakinra due to inefficacy or severe side
effects).
Results
At baseline, the mean age was 8.4 year (range 1-17 years)
with mean disease duration of 3.05 years (3 months-10.2
years). All patients had active arthritis (mean number of
active joints 12.3, range 1-80), 28/34 had fever, 20/34 had
skin rash. Failure of anti-TNF treatment or DMARD was
observed in 11/34 and 23/34 patients respectively.
Ongoing steroid treatment 33/34 patients (mean predni-
sone mg 0.87/kg/day, range 0.1- 3). The mean follow-up
was 4.02 year (range 1.05 - 6.16). At the last follow-up
13 patients (38%) were complete responders, 5 (14%) par-
tial responders and 16 (48%) non responder. Among com-
plete responders, 4 patients withdrawn anakinra without
relapses after a mean of 3 years of treatment, 7 are in
remission using anakinra as mono-therapy, 2 patients
were switched to anti IL-1 monoclonal antibody with
a full response. Despite the good control of their disease
11/13 displayed at least one relapse of their disease during
the follow-up with a total of 22 relapses (range 1-4
for patient). In 16 non responders patients subsequent
treatments were canakinumab (1 patient), tocilizumab
(5 patients), or combined immunosuppressive treatment
and/or anti-TNF (10 patients), with variable response.
Adverse events and complications: 13 Anakinra-treated
patients had skin reactions of variable intensity and dura-
tion, in 7 patients hitching was also present without an
evident skin rash. Six patients (3 responder and 3 non
responders) developed a MAS during follow-up. Two
non-responders patients died for acute bacterial meningitis
and multi-organ failure after an episode of MAS. As pre-
viously observed, responders patients confirmed to have
an higher number of active and limited joints at baseline
(p = 0.006) and higher WBC and neutrhophils count (p =
0.002). These results were confirmed in the newly enrolled
patients. In this latter group responder patients displayed
a significantly shorter disease duration in respect to non
responder patients (p = 0.03).
Conclusion
In responder SoJIA patients Anakinra confirm to be an
effective and safe drug in the long term. The use of Ana-
kinra is still able to dissect two distinct populations of SoJIA
patients on the basis of the presence or not of a severe joint
involvement with a chronic polyarticular course.
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